Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | FPR3 | P25089 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107614 | 0.84 | CNR1 (0.71) | CNR1MEN1KMT2APOLBMAPT | |
| SCHEMBL4123782 | 0.82 | MCHR1 (0.47) | CNR1MEN1KMT2AMAPTFPR3 | |
| SCHEMBL4115004 | 0.78 | CNR1 (0.59) | CNR1MEN1KMT2APOLBMAPT | |
| SCHEMBL4107606 | 0.78 | FPR3 (0.46) | TNIKFPR3FPR2L3MBTL1 | |
| SCHEMBL4118371 | 0.77 | EPHX2 (0.54) | CNR1MEN1KMT2AHTR3AMAPT | |
| SCHEMBL4123912 | 0.77 | EPHX2 (0.61) | CNR1MEN1KMT2APOLBHTR3A | |
| SCHEMBL4107145 | 0.77 | CNR1 (0.60) | CNR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4113123 | 0.77 | CNR1 (0.60) | CNR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4112231 | 0.76 | CNR1 (0.59) | CNR1MEN1KMT2APOLBMAPT | |
| SCHEMBL7510422 | 0.76 | MAPT (0.67) | CNR1TNIKMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | CNR1 3201/4885TNIK 392/4885MEN1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.